CN118830603A - Intestinal flora targeting formula food for improving diabetes and preparation method thereof - Google Patents
Intestinal flora targeting formula food for improving diabetes and preparation method thereof Download PDFInfo
- Publication number
- CN118830603A CN118830603A CN202411085298.0A CN202411085298A CN118830603A CN 118830603 A CN118830603 A CN 118830603A CN 202411085298 A CN202411085298 A CN 202411085298A CN 118830603 A CN118830603 A CN 118830603A
- Authority
- CN
- China
- Prior art keywords
- parts
- intestinal flora
- formula food
- improving
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 49
- 235000013305 food Nutrition 0.000 title claims abstract description 47
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 230000008685 targeting Effects 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 23
- 235000017060 Arachis glabrata Nutrition 0.000 claims abstract description 18
- 244000105624 Arachis hypogaea Species 0.000 claims abstract description 18
- 235000010777 Arachis hypogaea Nutrition 0.000 claims abstract description 18
- 235000018262 Arachis monticola Nutrition 0.000 claims abstract description 18
- 235000010523 Cicer arietinum Nutrition 0.000 claims abstract description 18
- 244000045195 Cicer arietinum Species 0.000 claims abstract description 18
- 235000020232 peanut Nutrition 0.000 claims abstract description 18
- 235000020238 sunflower seed Nutrition 0.000 claims abstract description 18
- 235000007340 Hordeum vulgare Nutrition 0.000 claims abstract description 17
- 229920001202 Inulin Polymers 0.000 claims abstract description 15
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 15
- 229940029339 inulin Drugs 0.000 claims abstract description 15
- 230000008569 process Effects 0.000 claims abstract description 15
- 241000209140 Triticum Species 0.000 claims abstract description 14
- 235000021307 Triticum Nutrition 0.000 claims abstract description 14
- 235000013312 flour Nutrition 0.000 claims abstract description 14
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 10
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 10
- 240000005979 Hordeum vulgare Species 0.000 claims abstract 5
- 239000000203 mixture Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 229920000294 Resistant starch Polymers 0.000 claims description 11
- 235000021254 resistant starch Nutrition 0.000 claims description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims description 11
- 230000001007 puffing effect Effects 0.000 claims description 10
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000001125 extrusion Methods 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 230000005070 ripening Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000010298 pulverizing process Methods 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 1
- 238000005194 fractionation Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 12
- 239000006041 probiotic Substances 0.000 abstract description 7
- 235000018291 probiotics Nutrition 0.000 abstract description 7
- 235000013406 prebiotics Nutrition 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 235000012000 cholesterol Nutrition 0.000 abstract description 3
- 235000013325 dietary fiber Nutrition 0.000 abstract description 3
- 230000008855 peristalsis Effects 0.000 abstract description 3
- 235000013339 cereals Nutrition 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 235000014571 nuts Nutrition 0.000 abstract description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004380 Cholic acid Substances 0.000 abstract 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 abstract 1
- 229960002471 cholic acid Drugs 0.000 abstract 1
- 235000019416 cholic acid Nutrition 0.000 abstract 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 241000209219 Hordeum Species 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 244000005709 gut microbiome Species 0.000 description 7
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241000736262 Microbiota Species 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000605980 Faecalibacterium prausnitzii Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 201000010603 frozen shoulder Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 235000021192 high fiber diet Nutrition 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000020793 low-cost food Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000009461 vacuum packaging Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 235000019683 whole nuts Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/143—Cereal granules or flakes to be cooked and eaten hot, e.g. oatmeal; Reformed rice products
- A23L7/148—Cereal granules or flakes to be cooked and eaten hot, e.g. oatmeal; Reformed rice products made from wholegrain or grain pieces without preparation of meal or dough
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/161—Puffed cereals, e.g. popcorn or puffed rice
- A23L7/165—Preparation of puffed cereals involving preparation of meal or dough as an intermediate step
- A23L7/17—Preparation of puffed cereals involving preparation of meal or dough as an intermediate step by extrusion
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Agronomy & Crop Science (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
技术领域Technical Field
本发明涉及一种改善人体生理机能的配方食品及其制备方法,具体涉及一种改善糖尿病的肠道菌群靶向配方食品及其制备方法。The present invention relates to a formula food for improving human physiological functions and a preparation method thereof, and in particular to an intestinal flora targeted formula food for improving diabetes and a preparation method thereof.
背景技术Background Art
糖尿病是一种由于胰岛素分泌不足或胰岛素作用受阻导致的慢性疾病,其特点是血糖水平的持续升高。糖尿病的发病原因可能包括遗传因素、环境因素(如肥胖、年龄增长、不良生活习惯等)、免疫因素以及妊娠等。糖尿病的典型症状被称为“三多一少”,即多饮、多尿、多食和体重减少。这些症状是由于高血糖导致尿液中葡萄糖含量增加,机体水分丢失增多,以及由于胰岛素缺乏或胰岛素抵抗导致葡萄糖不能被细胞利用,身体转而分解脂肪和蛋白质来提供能量。除此之外,还可能表现为餐前低血糖、疲乏无力、身体消瘦、局部皮肤变黑、视物模糊、胃肠道不适、出汗异常、直立性低血压、性功能障碍、手足麻木、肩周炎、牙龈发炎及牙齿松动、无痛性心梗等多种症状。治疗糖尿病需要综合药物、饮食控制、运动和血糖监测,对于部分患者可能需要胰岛素治疗 。Diabetes is a chronic disease caused by insufficient insulin secretion or blocked insulin action, characterized by a continuous increase in blood sugar levels. The causes of diabetes may include genetic factors, environmental factors (such as obesity, aging, bad living habits, etc.), immune factors, and pregnancy. The typical symptoms of diabetes are called "three mores and one less", namely, polydipsia, polyuria, polyphagia, and weight loss. These symptoms are due to the increase in glucose content in urine caused by high blood sugar, increased water loss in the body, and the inability of glucose to be used by cells due to insulin deficiency or insulin resistance, and the body turns to break down fat and protein to provide energy. In addition, it may also manifest as hypoglycemia before meals, fatigue, weight loss, local skin darkening, blurred vision, gastrointestinal discomfort, abnormal sweating, orthostatic hypotension, sexual dysfunction, numbness of hands and feet, frozen shoulder, gingivitis and loose teeth, painless myocardial infarction and other symptoms. The treatment of diabetes requires comprehensive medication, diet control, exercise and blood sugar monitoring, and some patients may need insulin treatment.
肠道菌群功能被发现以来,得到广泛的研究,被称为人体“第二大脑”,它参与物质代谢、合成,维持正常免疫功能,从心理到生理深刻影响着人体健康。肠道菌群不仅在维持机体正常生理功能方面发挥作用,而且与糖尿病的发生发展密切相关。糖尿病患者的肠道菌群在结构和功能上与正常人存在差异,这些差异可能通过影响宿主的代谢和免疫反应,进而影响糖尿病的发展。肠道菌群与糖尿病之间的关联可能涉及多种机制。一方面,肠道菌群参与了宿主的能量代谢和炎症反应,它们产生的代谢产物如短链脂肪酸(SCFAs)能够影响肠道抗炎反应能力、激活SCFAs受体,进而可能影响胰岛β细胞的功能和胰岛素的敏感性。另一方面,肠道菌群失调可能导致肠道屏障功能降低,增加肠道通透性,促使细菌脂多糖(如LPS)易位到血液循环中,引发代谢性内毒素血症和胰岛素抵抗。此外,一些特定的肠道菌群成员,如普拉梭菌,已被认为与糖尿病的发展有关。饮食模式的改变,特别是高纤维饮食,可以增加普拉梭菌的数量,从而可能有助于改善糖尿病状况。针对肠道菌群的治疗方法,如益生菌、益生元、粪便菌群移植等,已显示出改善肠道菌群组成和糖尿病症状的潜力。例如,益生菌的使用可能有助于调节肠道菌群,减少炎症,改善胰岛素敏感性。粪便菌群移植通过将健康供体的肠道菌群移植到患者体内,可能有助于重建肠道菌群平衡,提高胰岛素敏感性。肠道菌群受环境、饮食和宿主等因素影响,而饮食则是决定肠道菌群群落结构和功能的关键。通过饮食来调节菌群,从而调节宿主的生理机能,是公认的一种营养干预策略。Since the discovery of the function of intestinal flora, it has been widely studied. It is called the "second brain" of the human body. It participates in the metabolism and synthesis of substances, maintains normal immune function, and profoundly affects human health from psychology to physiology. The intestinal flora not only plays a role in maintaining the normal physiological function of the body, but is also closely related to the occurrence and development of diabetes. The intestinal flora of diabetic patients differs from that of normal people in structure and function. These differences may affect the development of diabetes by affecting the host's metabolism and immune response. The association between intestinal flora and diabetes may involve multiple mechanisms. On the one hand, intestinal flora participates in the host's energy metabolism and inflammatory response. The metabolites they produce, such as short-chain fatty acids (SCFAs), can affect the intestinal anti-inflammatory response ability and activate SCFAs receptors, which may affect the function of pancreatic β cells and insulin sensitivity. On the other hand, intestinal flora imbalance may lead to reduced intestinal barrier function, increased intestinal permeability, and promote the translocation of bacterial lipopolysaccharides (such as LPS) into the blood circulation, causing metabolic endotoxemia and insulin resistance. In addition, some specific members of the intestinal flora, such as Faecalibacterium prausnitzii, have been considered to be associated with the development of diabetes. Changes in dietary patterns, especially a high-fiber diet, can increase the number of Faecalibacterium prausnitzii, which may help improve diabetic conditions. Therapeutic approaches targeting the gut microbiota, such as probiotics, prebiotics, and fecal microbiota transplantation, have shown the potential to improve the composition of the gut microbiota and diabetic symptoms. For example, the use of probiotics may help regulate the gut microbiota, reduce inflammation, and improve insulin sensitivity. Fecal microbiota transplantation may help to re-establish the balance of the gut microbiota and improve insulin sensitivity by transplanting the gut microbiota from a healthy donor into the patient. The gut microbiota is affected by factors such as the environment, diet, and host, and diet is the key to determining the structure and function of the gut microbiota community. Regulating the microbiota through diet, thereby regulating the physiological function of the host, is a recognized nutritional intervention strategy.
肠道菌群靶向性食品(Microbiota-directed food, MDF),是指为改变消费者肠道菌群结构而设计的产品,与传统食品相比,MDF在设计时主要针对特定的肠道菌群,提供一些健康人体所需的可由微生物群进行转化的底物,对肠道菌群进行精准、定向调节,从而特异性改变肠道菌群的特征及功能特性。2024年4月25日召开的2024年国际食品安全与健康大会上,菌群靶向食品被列为全球食品安全与健康十大研究热点之一;开发一种面向广大糖尿病患者人群的、低成本的能改善糖尿病的肠道菌群靶向配方食品成为市场的一项迫切需要。Microbiota-directed food (MDF) refers to products designed to change the structure of consumers' intestinal flora. Compared with traditional foods, MDF is designed to target specific intestinal flora, provide some substrates that can be converted by microbiota and are needed by the healthy human body, and precisely and targetedly regulate the intestinal flora, thereby specifically changing the characteristics and functional properties of the intestinal flora. At the 2024 International Food Safety and Health Conference held on April 25, 2024, microbiota-targeted food was listed as one of the top ten research hotspots in global food safety and health; the development of a low-cost microbiota-targeted formula food that can improve diabetes for the general population of diabetic patients has become an urgent need in the market.
发明内容Summary of the invention
针对现有技术存在的上述不足,本发明的目的在于提供一种改善糖尿病的肠道菌群靶向配方食品及其制备方法,作为一种调控血糖的特色的、低成本的食品,适用于广大的糖尿病患者。In view of the above-mentioned deficiencies in the prior art, the purpose of the present invention is to provide a targeted intestinal flora formula food for improving diabetes and a preparation method thereof, which is a special and low-cost food for regulating blood sugar and is suitable for a large number of diabetic patients.
为了解决上述技术问题,本发明采用如下技术方案:In order to solve the above technical problems, the present invention adopts the following technical solutions:
一种改善糖尿病的肠道菌群靶向配方食品,其特征在于,其组分及其质量份数为:燕麦片5-20份、小麦或大麦粉5-20份、花生仁5-15份、鹰嘴豆5-15份、葵花籽5-15份、菊粉10-20份、低聚异麦芽糖5-20份和枯草芽孢杆菌5-10份。A targeted intestinal flora formula food for improving diabetes, characterized in that its components and their mass proportions are: 5-20 parts of oatmeal, 5-20 parts of wheat or barley flour, 5-15 parts of peanut kernels, 5-15 parts of chickpeas, 5-15 parts of sunflower seeds, 10-20 parts of inulin, 5-20 parts of isomaltooligosaccharide and 5-10 parts of Bacillus subtilis.
这样,本发明的改善糖尿病的肠道菌群靶向配方食品,以富含膳食纤维的杂粮、坚果为主,添加菊粉等益生元,并添加益生菌,可以促进肠道蠕动,增加有益菌的增长,有助于维持肠道微生物平衡,并促进胆固醇向胆酸转化,降低血液中的胆固醇水平。In this way, the intestinal flora targeted formula food for improving diabetes of the present invention is mainly composed of whole grains and nuts rich in dietary fiber, with added prebiotics such as inulin, and added probiotics, which can promote intestinal peristalsis, increase the growth of beneficial bacteria, help maintain the balance of intestinal microorganisms, promote the conversion of cholesterol into bile acid, and lower the cholesterol level in the blood.
进一步地,所述小麦或大麦粉为熟制产品。Furthermore, the wheat or barley flour is a cooked product.
进一步地,小麦或大麦粉碎至40—100目,调整水分至低于14%,使用双螺杆挤压膨化机,膨化I区温度120—135℃、膨化Ⅱ区温度135—145℃、膨化Ⅲ区温度145—160℃,螺杆80—150转/分钟;膨化后进一步干燥,降低物料水分含量至低于5%,再粉碎至80目或以下。Further, the wheat or barley is crushed to 40-100 mesh, the moisture content is adjusted to less than 14%, and a twin-screw extruder is used, with the temperature of the extrusion zone I being 120-135° C., the temperature of the extrusion zone II being 135-145° C., the temperature of the extrusion zone III being 145-160° C., and the screw speed being 80-150 rpm; after extrusion, the material is further dried to reduce the moisture content to less than 5%, and then crushed to 80 mesh or less.
进一步地,所述花生仁、葵花籽、鹰嘴豆均为切碎装置或粉碎装置粉碎后的颗粒。Furthermore, the peanut kernels, sunflower seeds and chickpeas are all particles crushed by a chopping device or a crushing device.
进一步地,所述花生仁、葵花籽、鹰嘴豆是烘烤或炒熟后的。Furthermore, the peanut kernels, sunflower seeds and chickpeas are roasted or fried.
进一步地,所述花生仁、葵花籽、鹰嘴豆的熟制产品的熟化制备方法为:按照工艺要求配备原料,进入烘烤炉内进行烘烤,炉温190-230℃,烘烤工艺要求的时间,然后出炉冷却,必要时(根据需要)进行脱皮,筛选后进行切碎或粉碎至30目以下。Furthermore, the ripening preparation method of the cooked products of peanut kernels, sunflower seeds and chickpeas is: prepare the raw materials according to the process requirements, put them into a baking furnace for baking, the furnace temperature is 190-230°C, the time required by the baking process, then take them out of the oven to cool, peel them if necessary (as needed), screen them, and then chop or crush them to less than 30 meshes.
进一步地,所述抗性淀粉采用的是回生淀粉。Furthermore, the resistant starch used is retrograded starch.
一种改善糖尿病的肠道菌群靶向配方食品的制备方法,其特征在于包括如下步骤:A method for preparing an intestinal flora targeted formula food for improving diabetes, characterized by comprising the following steps:
1、根据工艺要求,按照上述配比分别称取或准备食品的各组分;1. According to the process requirements, weigh or prepare the components of the food according to the above ratios;
2、采用多步分级法将各组分进行充分混合:2. Use multi-step classification method to fully mix the components:
2.1)将熟化后的小麦或大麦粉和燕麦片加入混合容器中均匀搅拌;2.1) Add the cooked wheat or barley flour and oat flakes into a mixing container and mix evenly;
2.2)将熟化后的花生仁、葵花籽、鹰嘴豆加入混合容器中均匀搅拌;2.2) Add the cooked peanut kernels, sunflower seeds and chickpeas into the mixing container and mix evenly;
2.3)按照工艺要求,将步骤2.2)中的混合物置于搅拌机中搅拌,搅拌期间依次加入菊粉、抗性淀粉、低聚异麦芽糖和枯草芽孢杆菌,继续搅拌混合均匀,得初步配方食品;2.3) According to the process requirements, the mixture in step 2.2) is placed in a blender and stirred, and inulin, resistant starch, isomaltooligosaccharide and Bacillus subtilis are added in sequence during stirring, and the stirring is continued until the mixture is evenly mixed to obtain a preliminary formula food;
3)按照工艺要求,将初步配方食品置于加热锅中小火翻炒,时间在5—40分钟;3) According to the process requirements, stir-fry the preliminary formula food in a heating pan over low heat for 5-40 minutes;
4)对翻炒后的产品进行灭菌处理;4) Sterilize the stir-fried product;
5)灭菌处理后进行分装。5) After sterilization, repackaging is carried out.
进一步地,所述的灭菌处理,采用微波灭菌处理,微波灭菌为功率600—1500W,样品量20—100g,处理时间1—10min.Furthermore, the sterilization treatment adopts microwave sterilization, the microwave sterilization power is 600-1500W, the sample amount is 20-100g, and the treatment time is 1-10min.
改善糖尿病的肠道菌群靶向配方食品的食用方法,其特征在于,用与包装袋所装的食品质量对应量的热水,进行搅拌冲泡,或加热煮沸后,直接饮用。The method for consuming the intestinal flora targeted formula food for improving diabetes is characterized by using hot water in an amount corresponding to the mass of the food in the packaging bag, stirring and brewing it, or heating and boiling it, and then drinking it directly.
本发明的改善糖尿病的肠道菌群靶向配方食品及其制备方法,相对现有技术,具有如下有益效果:The intestinal flora targeted formula food for improving diabetes and the preparation method thereof of the present invention have the following beneficial effects compared with the prior art:
1、本发明的改善糖尿病的肠道菌群靶向配方食品,以富含膳食纤维的杂粮、坚果为主,添加菊粉等益生元,并添加益生菌,可以促进肠道蠕动,增加有益菌的增长,有助于维持肠道微生物平衡,并促进胆固醇向胆酸转化,降低血液中的胆固醇水平;1. The intestinal flora targeted formula food for improving diabetes of the present invention is mainly composed of grains and nuts rich in dietary fiber, and is added with prebiotics such as inulin and probiotics, which can promote intestinal peristalsis, increase the growth of beneficial bacteria, help maintain the balance of intestinal microorganisms, and promote the conversion of cholesterol into bile acid, thereby reducing the cholesterol level in the blood;
2、本发明的改善糖尿病的肠道菌群靶向配方食品,能减缓消化过程中糖分的吸收,提高胰岛素受体的敏感性和胰岛素的利用率,从而有助于降低餐后血糖水平,改善长期血糖控制 。2. The intestinal flora targeted formula food for improving diabetes of the present invention can slow down the absorption of sugars during digestion, increase the sensitivity of insulin receptors and the utilization rate of insulin, thereby helping to lower postprandial blood sugar levels and improve long-term blood sugar control.
3、本发明的改善糖尿病的肠道菌群靶向配方食品,成本较低,适用广大的糖尿病患者长期食用。3. The intestinal flora targeted formula food for improving diabetes of the present invention has low cost and is suitable for long-term consumption by a wide range of diabetic patients.
4、本发明的制备方法工艺简单、适用,适合产业化生产的需要。4. The preparation method of the present invention is simple and applicable, and is suitable for the needs of industrial production.
具体实施方式DETAILED DESCRIPTION
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例,对本发明的技术方案进行清楚、完整地描述。显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
本发明一种改善糖尿病的肠道菌群靶向配方食品及其制备方法,其原料按重量(质量)份数组分为:燕麦片5-20份、小麦或大麦粉5-20份、花生仁5-15份、鹰嘴豆5-15份、葵花籽5-15份、菊粉10-20份、抗性淀粉10-20份(抗性淀粉根据来源的不同,分为RS1、RS2、RS3、RS4等)、低聚异麦芽糖5-20份、枯草芽孢杆菌5-10份。The invention discloses an intestinal flora targeted formula food for improving diabetes and a preparation method thereof. The raw materials are divided into the following groups according to weight (mass): 5-20 parts of oatmeal, 5-20 parts of wheat or barley flour, 5-15 parts of peanut kernels, 5-15 parts of chickpeas, 5-15 parts of sunflower seeds, 10-20 parts of inulin, 10-20 parts of resistant starch (resistant starch is divided into RS1, RS2, RS3, RS4, etc. according to different sources), 5-20 parts of isomaltooligosaccharide, and 5-10 parts of Bacillus subtilis.
作为本发明的进一步的技术方案,所述小麦或大麦粉为熟制产品。As a further technical solution of the present invention, the wheat or barley flour is a cooked product.
所述小麦或大麦粉的制备方法为:干燥小麦或大麦粉碎至60目左右,如40—100目,调整水分至低于14%,使用双螺杆挤压膨化机,膨化I区温度120—135℃、膨化Ⅱ区温度135—145℃、膨化Ⅲ区温度145—160℃,螺杆80—150转/分钟;膨化后进一步干燥,降低物料水分含量至低于5%,及时进行粉碎至80目或以下。The preparation method of the wheat or barley flour is as follows: dry wheat or barley is crushed to about 60 meshes, such as 40-100 meshes, the moisture content is adjusted to less than 14%, a twin-screw extruder is used, the temperature of the puffing zone I is 120-135° C., the temperature of the puffing zone II is 135-145° C., the temperature of the puffing zone III is 145-160° C., and the screw is 80-150 rpm; after puffing, further drying is performed to reduce the moisture content of the material to less than 5%, and crushing is performed to 80 meshes or less in time.
作为本发明的进一步的技术方案,所述花生仁、葵花籽、鹰嘴豆均为切碎装置或粉碎装置粉碎后的颗粒,最好是烘烤、炒熟等熟化后的熟制产品。As a further technical solution of the present invention, the peanut kernels, sunflower seeds and chickpeas are all particles crushed by a chopping device or a crushing device, preferably cooked products after being baked, fried or the like.
本发明所述花生仁、葵花籽、鹰嘴豆的熟化制备方法为:按照工艺要求精选、配备原料,进入烘烤炉内进行烘烤,炉温190-230℃,烘烤工艺要求的时间,通常至果仁断面金黄色、口感酥脆时,然后出炉冷却,必要时(根据工艺需要)进行脱皮,筛选后用切碎机进行切碎、或粉碎机粉碎至30目以下。The ripening preparation method of peanut kernels, sunflower seeds and chickpeas of the present invention comprises the following steps: selecting and preparing raw materials according to process requirements, baking them in a baking furnace at a temperature of 190-230° C. for a time required by the baking process, usually until the cross section of the kernels is golden yellow and the taste is crispy, then taking them out of the furnace to cool, peeling them if necessary (according to process requirements), screening them, chopping them with a shredder, or crushing them with a grinder to less than 30 meshes.
作为本发明的进一步的改进方案,所述菊粉为来源于菊苣的天然菊粉,聚合度2-60。As a further improvement of the present invention, the inulin is natural inulin derived from chicory, with a degree of polymerization of 2-60.
作为本发明的进一步的改进方案,所述抗性淀粉采用的是回生淀粉(老化淀粉)。As a further improvement of the present invention, the resistant starch used is retrograded starch (aged starch).
本发明所述改善糖尿病的肠道菌群靶向配方食品包括一下制备步骤:The intestinal flora targeted formula food for improving diabetes of the present invention comprises the following preparation steps:
1、根据工艺要求,按照上述配比分别称取或准备食品的各组分;1. According to the process requirements, weigh or prepare the components of the food according to the above ratios;
2、采用多步分级法将各组分进行充分混合;2. Use a multi-step classification method to fully mix the components;
2.1)将熟化后的小麦或大麦粉和燕麦片加入混合容器中均匀搅拌;2.1) Add the cooked wheat or barley flour and oat flakes into a mixing container and mix evenly;
2.2)将熟化后的花生仁、葵花籽、鹰嘴豆加入混合容器中均匀搅拌;2.2) Add the cooked peanut kernels, sunflower seeds and chickpeas into the mixing container and mix evenly;
2.3)按照工艺要求,将步骤2.2)中的混合物置于搅拌机中搅拌,搅拌期间依次或分别加入菊粉、抗性淀粉、低聚异麦芽糖和枯草芽孢杆菌,继续搅拌混合均匀,如搅拌15—40min,待完全混合后,得初步配方食品;2.3) According to the process requirements, the mixture in step 2.2) is placed in a blender and stirred. During the stirring period, inulin, resistant starch, isomaltooligosaccharide and Bacillus subtilis are added in sequence or separately, and the stirring is continued until the mixture is evenly mixed, such as stirring for 15-40 minutes. After the mixture is completely mixed, a preliminary formula food is obtained;
3、按照工艺要求,将初步配方食品置于加热锅中小火翻炒,时间在5—40分钟,至有淡淡香味,迅速移出;3. According to the process requirements, stir-fry the preliminary formula food in a heating pot over low heat for 5-40 minutes until a light fragrance appears, and then remove it quickly;
4、对翻炒后的产品进行灭菌处理;如可以采用微波灭菌处理,微波灭菌条件为功率600—1500W,样品量20—100g,处理时间1—10min;4. Sterilize the stir-fried product; for example, microwave sterilization can be used. The microwave sterilization conditions are power 600-1500W, sample size 20-100g, and processing time 1-10min;
5、灭菌处理后进行分装,如真空包装,50g/包、100g/包、200g/包等。5. After sterilization, repackaging is carried out, such as vacuum packaging, 50g/bag, 100g/bag, 200g/bag, etc.
本发明所述改善糖尿病的肠道菌群靶向配方食品的食用方法为,用与包装袋所装的食品质量对应量(适量)的热水,进行搅拌冲泡,或加热煮沸后,直接饮用。如50g对应500ml左右的热水(70-80℃),进行搅拌冲泡,或加热煮沸。The method of taking the intestinal flora targeted formula food for improving diabetes of the present invention is to use hot water (appropriate amount) corresponding to the mass of the food in the packaging bag, stir and brew, or heat and boil, and then drink directly. For example, 50g corresponds to about 500ml of hot water (70-80℃), stir and brew, or heat and boil.
实施例一Embodiment 1
本发明所制备的一种改善糖尿病的肠道菌群靶向配方食品,其原料按重量份组分为:燕麦片20份、大麦粉20份、花生仁(碎)10份、鹰嘴豆(碎)10份、葵花籽(碎)10份、菊粉10份、抗性淀粉10份、低聚异麦芽糖5份、枯草芽孢杆菌5份。The intestinal flora targeted formula food for improving diabetes prepared by the present invention comprises the following raw materials by weight: 20 parts of oatmeal, 20 parts of barley flour, 10 parts of peanut kernels (crushed), 10 parts of chickpeas (crushed), 10 parts of sunflower seeds (crushed), 10 parts of inulin, 10 parts of resistant starch, 5 parts of isomaltooligosaccharide, and 5 parts of Bacillus subtilis.
实施例二Embodiment 2
本发明所制备的一种改善糖尿病的肠道菌群靶向配方食品,其原料按重量份组分为:燕麦片10份、大麦粉10份、花生仁(碎)10份、鹰嘴豆(碎)10份、葵花籽(碎)10份、菊粉15份、抗性淀粉15份、低聚异麦芽糖10份、枯草芽孢杆菌10份。The intestinal flora targeted formula food for improving diabetes prepared by the present invention comprises the following raw materials by weight: 10 parts of oatmeal, 10 parts of barley flour, 10 parts of peanut kernels (crushed), 10 parts of chickpeas (crushed), 10 parts of sunflower seeds (crushed), 15 parts of inulin, 15 parts of resistant starch, 10 parts of isomaltooligosaccharide, and 10 parts of Bacillus subtilis.
实施例三Embodiment 3
本发明所制备的一种改善糖尿病的肠道菌群靶向配方食品,其原料按重量份组分为:燕麦片6份、大麦粉6份、花生仁(碎)6份、鹰嘴豆(碎)6份、葵花籽(碎)6份、菊粉20份、抗性淀粉20份、低聚异麦芽糖20份、枯草芽孢杆菌10份。The intestinal flora targeted formula food for improving diabetes prepared by the present invention comprises the following raw materials by weight: 6 parts of oatmeal, 6 parts of barley flour, 6 parts of peanut kernels (crushed), 6 parts of chickpeas (crushed), 6 parts of sunflower seeds (crushed), 20 parts of inulin, 20 parts of resistant starch, 20 parts of isomaltooligosaccharide, and 10 parts of Bacillus subtilis.
动物实验:检测本发明所制备的肠道菌群靶向配方食品是否有调节血糖作用。Animal experiment: Detect whether the intestinal flora targeted formula food prepared by the present invention has the effect of regulating blood sugar.
实验过程:取8周龄40只雄性昆明小鼠(KM),分为4组,每组10只,对照组和3个实验组;先用高热量饲料喂食1个月,连续7d腹腔注射30mg/kg体重剂量的STZ,建立糖尿病小鼠模型。然后将配方食品添加到饲料中进行混合(200g/kg的比例)作为实验组小鼠饲料,对照组食用未添加本发明配方食品的饲料,分别在0d、7d、14d、28d的时间进行血糖检测,第28d进行肠道菌群检测。测试结果如下:Experimental process: 40 male Kunming mice (KM) aged 8 weeks were divided into 4 groups, 10 mice in each group, a control group and 3 experimental groups; they were first fed with high-calorie feed for 1 month, and STZ was intraperitoneally injected at a dose of 30 mg/kg body weight for 7 consecutive days to establish a diabetic mouse model. Then the formula food was added to the feed and mixed (at a ratio of 200 g/kg) as the feed for the experimental group mice, and the control group consumed feed without the formula food of the present invention. Blood sugar was tested at 0d, 7d, 14d, and 28d, and intestinal flora was tested on the 28th day. The test results are as follows:
注:实验组一、二、三,分别对应的为上述实例一、二、三中的配方食品;以上数值表示为“mean ± SD”,n=10,*表示与对照组的显著性差异,*p<0.05, **p<0.05。Note: Experimental groups 1, 2 and 3 correspond to the formula foods in the above examples 1, 2 and 3, respectively; the above values are expressed as "mean ± SD", n=10, * indicates a significant difference from the control group, *p<0.05, **p<0.05.
从实验结果看出,食用本发明所制备的配方食品后,糖尿病小鼠的血糖出现了显著下降,肠道中益生菌双歧杆菌的丰度也出现明显上升,实验组一相对对照组上升达到58%,实验组二上升达到81%,实验组三上升达到90%,效果非常良好。From the experimental results, it can be seen that after eating the formula food prepared by the present invention, the blood sugar of diabetic mice decreased significantly, and the abundance of probiotic bifidobacterium in the intestine also increased significantly. The increase in experimental group 1 reached 58% relative to the control group, the increase in experimental group 2 reached 81%, and the increase in experimental group 3 reached 90%, and the effect was very good.
最后需要说明的是,以上实施例仅用以说明本发明的技术方案而非限制技术方案,本领域的普通技术人员应当理解,那些对本发明的技术方案进行修改或者等同替换,而不脱离本技术方案的宗旨和范围,均应涵盖在本发明的权利要求范围当中。Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the technical solution. Those skilled in the art should understand that those modifications or equivalent substitutions of the technical solution of the present invention that do not depart from the purpose and scope of the technical solution should be included in the scope of the claims of the present invention.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411085298.0A CN118830603A (en) | 2024-08-08 | 2024-08-08 | Intestinal flora targeting formula food for improving diabetes and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411085298.0A CN118830603A (en) | 2024-08-08 | 2024-08-08 | Intestinal flora targeting formula food for improving diabetes and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118830603A true CN118830603A (en) | 2024-10-25 |
Family
ID=93149981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411085298.0A Pending CN118830603A (en) | 2024-08-08 | 2024-08-08 | Intestinal flora targeting formula food for improving diabetes and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118830603A (en) |
-
2024
- 2024-08-08 CN CN202411085298.0A patent/CN118830603A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ng et al. | Incorporation of dietary fibre-rich oyster mushroom (Pleurotus sajor-caju) powder improves postprandial glycaemic response by interfering with starch granule structure and starch digestibility of biscuit | |
| Shin et al. | Formation, characterization, and glucose response in mice to rice starch with low digestibility produced by citric acid treatment | |
| Larrea et al. | Some functional properties of extruded orange pulp and its effect on the quality of cookies | |
| Agama-Acevedo et al. | Starch digestibility and glycemic index of cookies partially substituted with unripe banana flour | |
| CN109588695A (en) | A kind of preparation method of RS5 type wheat resistant starch | |
| CN104872558A (en) | Low-glycemic-index brewing porridge and preparation method thereof | |
| US20130142932A1 (en) | Processing and cooking of food with a low glycemic impact for the nutrition of diabetics, obese and for weight reducing diets | |
| Selma-Gracia et al. | Potential beneficial effect of hydrothermal treatment of starches from various sources on in vitro digestion | |
| Li | Resistant starch and its applications | |
| CN106689258A (en) | Low-glycemic-index waffle pre-mixed powder and making method thereof | |
| Bai et al. | A review of the design and architecture of starch-based dietary foods | |
| US6720312B2 (en) | Method for controlling the membrane structure of a starch granule | |
| CN101766281A (en) | Resistant starch rice noodles with good taste | |
| KR102300310B1 (en) | Method for manufacturing rice cake comprising dietary fiber and rice cake manufactured thereby | |
| US7053066B2 (en) | Food composition and weight loss method for treating obesity | |
| WO2010140182A1 (en) | Food compositions comprising flour, glucomannan and a mixture of soluble prebiotic fibres and process for the preparation thereof | |
| KR101288363B1 (en) | Functional five-coloured instant cup Tteokbokki Containing Dietary Fiber and Salicornia herbacea and a method of manufacturing the same | |
| CN104585584B (en) | A kind of high-resistance starch purple sweet potato vermicelli and preparation method thereof | |
| KR101301926B1 (en) | INSTANT GRUEL FOR DIABETIC PATIENT AND METHOD FOR PRODUCING THE SAME,and INSTANT GRUEL FOR primix | |
| CN118830603A (en) | Intestinal flora targeting formula food for improving diabetes and preparation method thereof | |
| CN116649530A (en) | Meal replacement powder containing high-resistance starch rice flour and preparation method thereof | |
| KR20060092842A (en) | Use of Chemically Modified Starch Products | |
| NL2034665B1 (en) | High-nutrition rs2 high-resistant starch noodle and preparation method thereof | |
| Abdulmageed et al. | The health importance of resistant starch in some agricultural crops: A review | |
| CN112641024A (en) | Solid beverage and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |